GOSSAMER BIO, INC. Increase (Decrease) in Employee Related Liabilities
GOSSAMER BIO, INC. (GOSS) reported Increase (Decrease) in Employee Related Liabilities of -$2.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2026-08-13
- GOSSAMER BIO, INC. increase (decrease) in employee related liabilities for the quarter ending 2026-06-30 was -$3.59M, a 219.14% decline year-over-year.
- GOSSAMER BIO, INC. increase (decrease) in employee related liabilities for the quarter ending 2026-03-31 was $1.44M.
- GOSSAMER BIO, INC. increase (decrease) in employee related liabilities for the quarter ending 2025-12-31 was -$759.00K, a 138.12% decline year-over-year.
- GOSSAMER BIO, INC. increase (decrease) in employee related liabilities for the quarter ending 2025-09-30 was $2.81M, a 28.50% increase year-over-year.
- GOSSAMER BIO, INC. increase (decrease) in employee related liabilities for fiscal 2025 was -$784.00K, a 146.09% decline from fiscal 2024.
- GOSSAMER BIO, INC. increase (decrease) in employee related liabilities for fiscal 2024 was $1.70M.
- GOSSAMER BIO, INC. increase (decrease) in employee related liabilities for fiscal 2023 was -$3.24M, a 300.25% decline from fiscal 2022.
- GOSSAMER BIO, INC. increase (decrease) in employee related liabilities for fiscal 2022 was $1.62M.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.15M 10-Q · filed 2026-08-13 | -$2.91M derived: sum of 3 quarters · filed 2026-08-13 | -$101.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.44M 10-Q · filed 2026-05-15 | $676.00K derived: sum of 2 quarters · filed 2026-05-15 | $3.48M derived: sum of 3 quarters · filed 2026-05-15 | $6.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$759.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.05M derived: sum of 2 quarters · filed 2026-03-17 | $5.06M derived: sum of 3 quarters · filed 2026-08-13 | -$784.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | $2.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.82M derived: sum of 2 quarters · filed 2026-08-13 | -$25.00K 10-Q · filed 2025-11-05 | $1.97M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $3.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.83M 10-Q · filed 2026-08-13 | -$843.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.34M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$5.84M 10-Q · filed 2026-05-15 | -$3.85M derived: sum of 2 quarters · filed 2026-05-15 | -$1.67M derived: sum of 3 quarters · filed 2026-05-15 | $435.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $4.18M derived: sum of 2 quarters · filed 2026-03-17 | $6.28M derived: sum of 3 quarters · filed 2026-03-17 | $1.70M 10-K · filed 2026-03-17 |
| 2024-09-30 | $2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.29M derived: sum of 2 quarters · filed 2025-11-05 | -$290.00K 10-Q · filed 2025-11-05 | $953.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$2.48M 10-Q · filed 2025-08-05 | -$1.23M derived: sum of 3 quarters · filed 2026-03-17 | -$381.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | -$4.58M 10-Q · filed 2025-05-15 | -$3.33M derived: sum of 2 quarters · filed 2026-03-17 | -$2.48M derived: sum of 3 quarters · filed 2026-03-17 | $299.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.10M derived: sum of 2 quarters · filed 2026-03-17 | $4.88M derived: sum of 3 quarters · filed 2026-03-17 | -$3.24M 10-K · filed 2026-03-17 |
| 2023-09-30 | $852.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.63M derived: sum of 2 quarters · filed 2024-11-07 | -$4.48M 10-Q · filed 2024-11-07 | -$1.45M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $2.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$5.33M 10-Q · filed 2024-08-12 | -$2.30M derived: sum of 3 quarters · filed 2025-03-13 | -$531.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | -$8.12M 10-Q · filed 2024-05-07 | -$5.08M derived: sum of 2 quarters · filed 2025-03-13 | -$3.31M derived: sum of 3 quarters · filed 2025-03-13 | -$697.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $3.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $4.80M derived: sum of 2 quarters · filed 2025-03-13 | $7.42M derived: sum of 3 quarters · filed 2025-03-13 | $1.62M 10-K · filed 2025-03-13 |
| 2022-09-30 | $1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.39M derived: sum of 2 quarters · filed 2023-11-09 | -$1.42M 10-Q · filed 2023-11-09 | $2.23M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $2.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$3.19M 10-Q · filed 2023-08-08 | $454.00K derived: sum of 3 quarters · filed 2024-03-05 | $794.00K derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | -$5.80M 10-Q · filed 2023-05-09 | -$2.16M derived: sum of 2 quarters · filed 2024-03-05 | -$1.82M derived: sum of 3 quarters · filed 2024-03-05 | $420.00K derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $3.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $3.98M derived: sum of 2 quarters · filed 2024-03-05 | $6.22M derived: sum of 3 quarters · filed 2024-03-05 | -$278.00K 10-K · filed 2024-03-05 |
| 2021-09-30 | $340.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $2.58M derived: sum of 2 quarters · filed 2022-11-03 | -$3.92M 10-Q · filed 2022-11-03 | -$347.00K derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-06-30 | $2.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$4.26M 10-Q · filed 2022-08-09 | -$687.00K derived: sum of 3 quarters · filed 2023-03-17 | $329.00K derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-03-31 | -$6.50M 10-Q · filed 2022-05-10 | -$2.93M derived: sum of 2 quarters · filed 2023-03-17 | -$1.91M derived: sum of 3 quarters · filed 2023-03-17 | $745.00K derived: sum of 4 quarters · filed 2023-03-17 |
| 2020-12-31 | $3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $4.59M derived: sum of 2 quarters · filed 2023-03-17 | $7.25M derived: sum of 3 quarters · filed 2023-03-17 | $1.61M 10-K · filed 2023-03-17 |
| 2020-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $3.67M derived: sum of 2 quarters · filed 2021-11-08 | -$1.96M 10-Q · filed 2021-11-08 | $958.00K derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | $2.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$2.98M 10-Q · filed 2021-08-09 | -$58.00K derived: sum of 3 quarters · filed 2022-03-03 | $2.02M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-03-31 | -$5.63M 10-Q · filed 2021-05-06 | -$2.72M derived: sum of 2 quarters · filed 2022-03-03 | -$641.00K derived: sum of 3 quarters · filed 2022-03-03 | $1.12M derived: sum of 4 quarters · filed 2022-03-03 |
| 2019-12-31 | $2.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $4.99M derived: sum of 2 quarters · filed 2022-03-03 | $6.75M derived: sum of 3 quarters · filed 2022-03-03 | $5.18M 10-K · filed 2022-03-03 |
| 2019-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $3.83M derived: sum of 2 quarters · filed 2020-11-10 | $2.26M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $188.00K 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | -$1.57M 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-26 | |||
| 2018-03-31 | $593.00K 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |